Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16) 16
oncology (15) 15
humans (13) 13
cancer (10) 10
lung cancer (9) 9
aged (8) 8
metastasis (8) 8
tumors (8) 8
carcinoma, non-small-cell lung - drug therapy (7) 7
female (7) 7
lung cancer, non-small cell (7) 7
breast cancer (6) 6
kinases (6) 6
middle aged (6) 6
proteins (6) 6
adult (5) 5
angiogenesis (5) 5
carcinoma, non-small-cell lung - pathology (5) 5
care and treatment (5) 5
expression (5) 5
lung neoplasms - drug therapy (5) 5
male (5) 5
research (5) 5
carcinoma, non-small-cell lung - genetics (4) 4
chemotherapeutics (4) 4
diagnosis (4) 4
metastases (4) 4
mice (4) 4
phosphorylation (4) 4
proliferation (4) 4
protein kinase inhibitors - therapeutic use (4) 4
receptor protein-tyrosine kinases - antagonists & inhibitors (4) 4
risk factors (4) 4
studies (4) 4
abridged index medicus (3) 3
adenocarcinoma (3) 3
antineoplastic agents - therapeutic use (3) 3
antisense (3) 3
apoptosis (3) 3
article (3) 3
breast (3) 3
breast-cancer (3) 3
chemotherapy (3) 3
clinical-significance (3) 3
gefitinib (3) 3
hematology, oncology and palliative medicine (3) 3
inhibition (3) 3
invasiveness (3) 3
kaplan-meier estimate (3) 3
lung neoplasms - metabolism (3) 3
lung neoplasms - pathology (3) 3
medical colleges (3) 3
medicine, research & experimental (3) 3
mutation (3) 3
mutations (3) 3
oncology, experimental (3) 3
phytochemicals (3) 3
pyrazoles - therapeutic use (3) 3
pyridines - therapeutic use (3) 3
rlip (3) 3
transport (3) 3
tumor cells (3) 3
tumor-growth (3) 3
aged, 80 and over (2) 2
akt protein (2) 2
analysis (2) 2
animal models (2) 2
animals (2) 2
antibodies (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
brain metastases (2) 2
cancer therapies (2) 2
carboplatin (2) 2
carcinoma, non-small-cell lung - enzymology (2) 2
carcinoma, non-small-cell lung - metabolism (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
cardiology and cardiovascular medicine (2) 2
cardiothoracic surgery (2) 2
cell cycle (2) 2
cell migration (2) 2
citrus fruits (2) 2
clinical trials (2) 2
complications and side effects (2) 2
ct imaging (2) 2
depletion (2) 2
dosage and administration (2) 2
eml4-alk fusion gene (2) 2
epidermal growth factor (2) 2
erbb-2 protein (2) 2
evaluation (2) 2
fibroblast growth factor (2) 2
gene amplification (2) 2
gene rearrangement (2) 2
genetic aspects (2) 2
glutathione-conjugate (2) 2
health aspects (2) 2
histology (2) 2
immunoglobulins (2) 2
immunohistochemistry (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups
by Jaklitsch, Michael T., MD and Jacobson, Francine L., MD, MPH and Austin, John H.M., MD and Field, John K., MA, PhD BDS, FRCPath and Jett, James R., MD and Keshavjee, Shaf, MSc, FRCSC, MD and MacMahon, Heber, MB, BCh and Mulshine, James L., MD and Munden, Reginald F., MD, DMD, MBA and Salgia, Ravi, MD, PhD and Strauss, Gary M., MD and Swanson, Scott J., MD and Travis, William D., MD and Sugarbaker, David J., MD
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2012, Volume 144, Issue 1, pp. 33 - 38
Objective Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography screening can reduce lung cancer–specific mortality... 
Cardiothoracic Surgery | SURGERY | RESPIRATORY SYSTEM | CARDIAC & CARDIOVASCULAR SYSTEMS | Smoking - adverse effects | United States - epidemiology | Tomography, X-Ray Computed - standards | Age Factors | Risk Assessment | Comorbidity | Humans | Middle Aged | Risk Factors | Mass Screening - standards | Radiation Dosage | Advisory Committees | Lung Neoplasms - epidemiology | Canada - epidemiology | Smoking - epidemiology | Lung Neoplasms - diagnostic imaging | Aged | Population Surveillance | Thoracic Surgical Procedures - standards | CT imaging | Medical colleges | Surgery | Oncology, Experimental | Lung cancer | Tomography | Diagnosis | Research | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy
by Allen, Michael J., PhD and Kanteti, Rajani, PhD and Riehm, Jacob J., MS and El-Hashani, Essam, MD and Salgia, Ravi, MD, PhD
Nanomedicine: Nanotechnology, Biology, and Medicine, ISSN 1549-9634, 2015, Volume 11, Issue 8, pp. 1971 - 1974
Abstract The 3D surface of Caenorhabditis elegans was imaged at nanometer resolution using atomic force microscopy (AFM). Oscillation of a medium stiffness... 
Internal Medicine | AFM | Atomic force microscopy | C. elegans | MEDICINE, RESEARCH & EXPERIMENTAL | NANOSCIENCE & NANOTECHNOLOGY | C-ELEGANS | Caenorhabditis elegans - ultrastructure | Animals | Caenorhabditis elegans - genetics | Imaging, Three-Dimensional - methods | Microscopy, Atomic Force - methods | Mutation | Caenorhabditis elegans - anatomy & histology | Caenorhabditis elegans | Nematoda | Microscope and microscopy | atomic force microscopy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Development of The American Association for Thoracic Surgery guidelines for low-dose computed tomography scans to screen for lung cancer in North America
by Jacobson, Francine L., MD, MPH and Austin, John H.M., MD and Field, John K., MA, PhD BDS, FRCPath and Jett, James R., MD and Keshavjee, Shaf, MSc, FRCSC, MD and MacMahon, Heber, MB, BCh and Mulshine, James L., MD and Munden, Reginald F., MD, DMD, MBA and Salgia, Ravi, MD, PhD and Strauss, Gary M., MD and Sugarbaker, David J., MD and Swanson, Scott J., MD and Travis, William D., MD and Jaklitsch, Michael T., MD
Journal of Thoracic and Cardiovascular Surgery, The, ISSN 0022-5223, 2012, Volume 144, Issue 1, pp. 25 - 32
Objective The study objective was to establish The American Association for Thoracic Surgery (AATS) lung cancer screening guidelines for clinical practice.... 
Cardiothoracic Surgery | CT imaging | Medical colleges | Surgery | Oncology, Experimental | Lung cancer | Tomography | Diagnosis | Research | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
by Shaw, Alice T, Dr and Yeap, Beow Y, ScD and Solomon, Benjamin J, MD and Riely, Gregory J, MD and Gainor, Justin, MD and Engelman, Jeffrey A, MD and Shapiro, Geoffrey I, MD and Costa, Daniel B, MD and Ou, Sai-Hong I, MD and Butaney, Mohit, BS and Salgia, Ravi, Prof and Maki, Robert G, MD and Varella-Garcia, Marileila, Prof and Doebele, Robert C, MD and Bang, Yung-Jue, Prof and Kulig, Kimary, PhD and Selaru, Paulina, MSPH and Tang, Yiyun, PhD and Wilner, Keith D, PhD and Kwak, Eunice L, MD and Clark, Jeffrey W, MD and Iafrate, A John, MD and Camidge, D Ross, MD
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Summary Background ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK... 
Hematology, Oncology and Palliative Medicine | ANAPLASTIC LYMPHOMA KINASE | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | PHASE-III | 2P23 | HISTOLOGY | TUMORS | ACTIVATING MUTATIONS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Patient Selection | Multicenter Studies as Topic | Time Factors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Retrospective Studies | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Risk Assessment | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Australia | Clinical Trials, Phase I as Topic | Care and treatment | Analysis | Patient outcomes | Genetic research | Genetic aspects | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study
by Camidge, D Ross, Dr and Bang, Yung-Jue, Prof and Kwak, Eunice L, MD and Iafrate, A John, MD and Varella-Garcia, Marileila, Prof and Fox, Stephen B, Prof and Riely, Gregory J, MD and Solomon, Benjamin, MBBS and Ou, Sai-Hong I, MD and Kim, Dong-Wan, Prof and Salgia, Ravi, Prof and Fidias, Panagiotis, MD and Engelman, Jeffrey A, MD and Gandhi, Leena, MD and Jänne, Pasi A, MD and Costa, Daniel B, MD and Shapiro, Geoffrey I, MD and LoRusso, Patricia, DO and Ruffner, Katherine, MD and Stephenson, Patricia, ScD and Tang, Yiyun, PhD and Wilner, Keith, PhD and Clark, Jeffrey W, MD and Shaw, Alice T, MD
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 10, pp. 1011 - 1019
Summary Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | ONCOLOGY | EML4-ALK FUSION GENE | C-MET | KINASE | ACQUIRED-RESISTANCE | ANAPLASTIC LYMPHOMA | CLINICAL-FEATURES | INHIBITOR | REARRANGEMENTS | EGFR | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Lung Neoplasms - enzymology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Pyridines - adverse effects | Protein Kinase Inhibitors - therapeutic use | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Pyrazoles - adverse effects | Pyridines - therapeutic use | Care and treatment | Safety and security measures | Genes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Activity and safety of brigatinib in ALK -rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
by Gettinger, Scott N, Dr and Bazhenova, Lyudmila A, Prof and Langer, Corey J, Prof and Salgia, Ravi, Prof and Gold, Kathryn A, MD and Rosell, Rafael, Prof and Shaw, Alice T, MD and Weiss, Glen J, MD and Tugnait, Meera, PhD and Narasimhan, Narayana I, PhD and Dorer, David J, PhD and Kerstein, David, MD and Rivera, Victor M, PhD and Clackson, Timothy, PhD and Haluska, Frank G, MD and Camidge, David Ross, Prof
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1683 - 1696
Summary Background Anaplastic lymphoma kinase ( ALK ) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is... 
Hematology, Oncology and Palliative Medicine | CRIZOTINIB-RESISTANT | ONCOLOGY | CERITINIB | TYROSINE KINASE | DOSE PROPORTIONALITY | ALECTINIB | BRAIN METASTASES | EXPERIENCE | INHIBITORS | MUTATIONS | CHEMOTHERAPY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Organophosphorus Compounds - adverse effects | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Organophosphorus Compounds - therapeutic use | Male | Protein Kinase Inhibitors - adverse effects | Receptor Protein-Tyrosine Kinases - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Gene Rearrangement | Pyrimidines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Medical colleges | Lymphomas | Research institutes | Lung cancer, Non-small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer
by Salgia, Ravi
Cancer, ISSN 0008-543X, 09/2011, Volume 117, Issue 17, pp. 3889 - 3899
Currently, nonsmall‐cell lung cancer (NSCLC) is the leading cause of cancer‐related death in the United States. Angiogenesis, the formation of new vasculature,... 
antiangiogenic therapy | fibroblast growth factor | NSCLC | angiogenesis | vascular endothelial growth factor | platelet‐derived growth factor | biomarker | platelet-derived growth factor | TARGETED THERAPY | COLLAGEN-XVIII | MICROVESSEL DENSITY | TUMOR ANGIOGENESIS | ADHESION MOLECULES | FACTOR RECEPTOR | VEGF MESSENGER-RNA | ONCOLOGY | SERUM-LEVELS | PATIENT SURVIVAL | CLINICAL-SIGNIFICANCE | Lung Neoplasms - drug therapy | Prognosis | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - blood supply | Humans | Carcinoma, Non-Small-Cell Lung - metabolism | Neovascularization, Pathologic | Vascular Endothelial Growth Factor A - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Receptors, Vascular Endothelial Growth Factor - metabolism | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Angiogenic Proteins - metabolism | Lung Neoplasms - blood supply | Care and treatment | Lung cancer | Physiological aspects | Causes of | Neovascularization | Research | Metastasis | Lung cancer, Non-small cell | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy
by Sattler, Martin and Salgia, Ravi
Current Oncology Reports, ISSN 1523-3790, 1/2007, Volume 9, Issue 2, pp. 102 - 108
Receptor tyrosine kinases have come to fruition as therapeutic targets in a variety of malignancies. In this group of targets, the c-Met receptor tyrosine... 
Medicine & Public Health | Oncology | Neoplasms - metabolism | Neoplasms - therapy | Proto-Oncogene Proteins c-met - physiology | Animals | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Humans | Antineoplastic Agents - therapeutic use | Hepatocyte Growth Factor - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Fibroblast growth factor signaling and inhibition in non‐small cell lung cancer and their role in squamous cell tumors
by Salgia, Ravi
Cancer Medicine, ISSN 2045-7634, 06/2014, Volume 3, Issue 3, pp. 681 - 692
With the introduction of targeted agents primarily applicable to non‐small cell lung cancer (NSCLC) of adenocarcinoma histology, there is a heightened unmet... 
fibroblast growth factors | Angiogenesis inhibitors | non‐small cell lung cancer | squamous cell carcinoma | non-small cell lung cancer | GENE-MUTATIONS | BLADDER-CANCER | PROGNOSTIC IMPACT | SOMATIC MUTATIONS | PHASE-II TRIAL | RECEPTOR TYROSINE KINASES | ONCOLOGY | MULTIPLE-MYELOMA PATIENTS | PROSTATE-CANCER | ANGIOGENESIS INHIBITOR | FGFR3 MUTATIONS | Carcinoma, Non-Small-Cell Lung - pathology | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Fibroblast Growth Factors - genetics | Clinical Trials as Topic | Molecular Targeted Therapy | Indoles - administration & dosage | Neovascularization, Pathologic - pathology | Neoplasms, Squamous Cell - genetics | Neovascularization, Pathologic - drug therapy | Neoplasms, Squamous Cell - drug therapy | Receptors, Fibroblast Growth Factor - genetics | Neovascularization, Pathologic - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Fibroblast Growth Factors - antagonists & inhibitors | Neoplasms, Squamous Cell - pathology | Lung cancer, Small cell | Squamous cell carcinoma | Fibroblast growth factors | Lung cancer, Non-small cell | Tumors | Adenocarcinoma | Fibroblast growth factor | Gemcitabine | Lung cancer | Clinical trials | Kinases | Cancer therapies | Proteins | Angiogenesis | Signal transduction | Fibroblasts | Growth factors | Protein-tyrosine kinase | Heparan sulfate | Tyrosine | Non-small cell lung carcinoma | Histology | Cisplatin | Gene amplification | Chemotherapy | Ligands | Mutation | Fibroblast growth factor receptors | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text RLIP inhibition suppresses breast-to-lung metastasis
by Singhal, Jyotsana and Singhal, Sharad S and Chikara, Shireen and Horne, David and Salgia, Ravi and Awasthi, Sanjay
Cancer Letters, ISSN 0304-3835, 04/2019, Volume 447, pp. 24 - 32
Breast tumor metastasis is a leading cause of cancer-related deaths worldwide. Breast cancer (BC) cells frequently metastasize to the lungs, where they pose a... 
Breast cancer | Chemotherapeutics | Phytochemicals | Metastasis | Lung | RLIP | REGRESSION | FLAVANONE | CANCER CELLS | 2'-HYDROXYFLAVANONE | CELL-CYCLE ARREST | PROLIFERATION | INDUCTION | TRANSPORT | ONCOLOGY | TUMOR-GROWTH | EXPRESSION | Viral antibodies | Antibodies | Evaluation | Cellular signal transduction | Progesterone | Estrogen | Phosphorylation | Motility | Antisense | Metastases | Proteins | Angiogenesis | Cell cycle | Inhibition | Citrus fruits | Immunoglobulins | Invasiveness | Studies | Depletion | Lungs | Cell lines | Weight reduction | Breast | Protein expression | Mice | Prostate | Viability | Cancer | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2′-Hydroxyflavanone
by Singhal, Jyotsana and Singhal, Preeti and Singhal, Sharad S and Horne, David and Salgia, Ravi and Awasthi, Sanjay
Cancer Letters, ISSN 0304-3835, 12/2018, Volume 438, pp. 144 - 153
Brain metastasis is an important cause of morbidity and mortality in cancer-patients. Breast tumor cells frequently metastasize to brain and initiate severe... 
Breast cancer | Chemotherapeutics | Phytochemicals | Brain metastasis | RLIP | GLUTATHIONE-CONJUGATE | PROLIFERATION | LUNG-CANCER CELLS | EFFECTOR | TRANSPORT | ONCOLOGY | RAL PATHWAY | EXPRESSION | GTPASE | ENDOTHELIAL GROWTH-FACTOR | Heart | Evaluation | Health aspects | Brain tumors | Imaging systems | Neuroimaging | Brain | Animal models | Clinical trials | Metastasis | Kinases | Cancer therapies | Metastases | Fruits | Angiogenesis | Cell cycle | Vascular endothelial growth factor | Immunoglobulins | Medical imaging | Complications | Tumor cells | Invasiveness | Morbidity | Studies | Brain research | Breast | Mice | Ventricle | Prostate | Cell migration | Cancer | Apoptosis | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights